Post-CAR Therapy BCR/TCR Immune Repertoire Clonality & Diversity Analysis (BCR/TCR-Seq) Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Despite durable remissions in some patients, CAR-T therapy faces significant hurdles, including antigen escape, relapse, and incomplete reconstitution of humoral and cellular immunity. To address these post-therapeutic complexities, we offer Post-CAR Therapy BCR/TCR Immune Repertoire Clonality & Diversity Analysis (BCR/TCR-Seq). Our service provides high-resolution profiling of B cell receptor and T cell receptor repertoires from peripheral blood or tumor samples, capturing clonal expansion, diversity indices, and lineage tracking. Leveraging advanced bioinformatics and proprietary algorithms, our analysis delivers actionable insights into immune recovery, minimal residual disease monitoring, and relapse prediction, empowering you to optimize patient-specific follow-up strategies.

Introduction

The T cell receptor (TCR) is a highly polymorphic heterodimeric complex expressed on the surface of T lymphocytes, enabling the specific recognition of peptide antigens presented in the context of major histocompatibility complex (MHC) molecules, thereby serving as the cornerstone of cellular adaptive immunity. In parallel, the B cell receptor (BCR), which is essentially a membrane-bound form of immunoglobulin, mediates direct antigen recognition through its variable regions, initiating humoral immune responses and subsequently undergoing affinity maturation and class switching upon antigen encounter. The high-throughput sequencing of TCR and BCR repertoires has revolutionized immunology by providing an unprecedented, quantitative lens into the clonal dynamics, diversity, and antigen-specific selection of lymphocyte populations, offering critical insights into immune surveillance, autoimmunity, vaccine efficacy, and the tumor–immune interface.

Fig.1 Profiling the repertoires of TCRs and BCRs via sequencing. (OA Literature) Fig.1 T cell receptor and B cell receptor sequencing.¹

Our Service

As a pioneer in cellular immunotherapy analytics, our Post-CAR Therapy BCR/TCR-Seq delivers high-resolution mapping of immune repertoire clonality and diversity. Our service enables precise tracking of clonal expansion, relapse risk prediction, and functional immune reconstitution assessment. Leveraging deep sequencing and advanced bioinformatics, we provide actionable insights to optimize combination strategies and evaluate long-term treatment efficacy, empowering clinicians with definitive data for informed decision-making.

What We Can Offer

Our BCR/TCR immune repertoire analysis delivers a comprehensive post-CAR-T evaluation framework, integrating clonality quantification, longitudinal clone tracking, and BCR phylogenetic reconstruction to decode immune reconstitution dynamics, identify clinically relevant clonal signatures, and illuminate antigen-driven selective pressures governing therapeutic outcomes.

Featured services of post-CAR therapy BCR/TCR immune repertoire clonality & diversity analysis (BCR/TCR-Seq) at Creative Biolabs. (Creative Biolabs Original)

Our Service Process

Required Starting Materials:

Sample type: Must be a high-quality individual cell suspension, typically derived from freshly isolated PBMCs or cells following tissue dissociation.
Cell requirements: Cell viability is generally required to be >80%, and the total cell number should be >5 × 10⁴ cells.

Key Steps:

Workflow of post-CAR therapy BCR/TCR immune repertoire clonality & diversity analysis (BCR/TCR-Seq) at Creative Biolabs. (Creative Biolabs Original)

Final Deliverables:

Raw data: FASTQ files and QC report with cell and molecular barcode information.
Core tables: Clonotype tables with chain pairing, full receptor sequences, and V(D)J gene usage per cell.
Clonality & diversity.

Key Advantages

Enhanced Resolution over Phenotyping: Goes beyond simple cell enumeration to precisely define the maturational state of regenerating B-cell pools via clonal architecture.
Prognostic Biomarker for Durable Remission: Endogenous T cell clonal expansion kinetics serve as a powerful predictor for long-term clinical outcomes post-therapy.
Unraveling Cryptic Clonal Evolution: Uniquely capable of tracking the emergence and outgrowth of subclinical clones that drive secondary relapses.
Functional-Molecular Clone Mapping: Integrates clonotype with transcriptomic data to directly link specific T-cell subsets to effector or regulatory functions.

FAQ

Q1: Why prioritize BCR/TCR repertoire analysis over flow cytometry post-CAR-T?

A1: BCR/TCR sequencing surpasses flow cytometry by not only quantifying B-cell abundance but also resolving their developmental maturation state. Critically, it reveals that sustained remission depends on the clonal expansion and cytotoxic polarization of endogenous T-cells, not merely CAR-T persistence, establishing repertoire analysis as a superior functional barometer of immune reconstitution.

Q2: What are the essential technical pitfalls in BCR versus TCR clonotype definition?

A2: The pivotal distinction is that TCR clonotypes are defined by exact CDR3 nucleotide matching, whereas BCRs undergo somatic hypermutation, necessitating nucleotide-distance-based clustering to group related lineages; applying exact matching to BCRs would falsely fragment clones. Additionally, individual cell data must be rigorously filtered to exclude doublets presenting dual chains.

Why Choose Us?

Our post‑CAR BCR/TCR‑seq delivers ultra‑deep clonotype tracking, quantitative diversity metrics, and longitudinal convergence analysis. We distinguish treatment‐specific repertoire shifts from background noise, enabling precise relapse prediction and immune recovery monitoring.

Customer Reviews

"Employing Creative Biolabs' TCRB sequencing platform, we profiled the clonal architecture of infused products and post-infusion peripheral blood in B cell malignancy patients receiving CD19-directed CAR-T therapy. Our data revealed that clonal diversity peaked within the infusion product and progressively contracted following adoptive transfer, providing critical insights into the transcriptional programs governing the long-term persistence and functional trajectory of engrafted CAR-T clones." Dr. J* A. F*.

"In a separate cohort of patients with relapsed/refractory B cell non-Hodgkin lymphoma, we applied Creative Biolabs's TCR sequencing service to map repertoire dynamics across multiple longitudinal time points. Comparative analysis between complete responders and non-responders demonstrated that patients achieving durable remission exhibited markedly enhanced clonal expansion of tumor-recirculating CD8⁺ effector memory T cells and activated peripheral memory CD8⁺ T cells at the one-month landmark, distinguishing favorable outcomes from relapsed or refractory disease." Dr. Y* L*.

How to contact us?

Ready to decode your CAR therapy's true efficacy? Maximize your clinical insights with our precision Post-CAR Therapy BCR/TCR-Seq services. Our immunity experts provide tailored immune repertoire clonality and diversity analysis to track expansion and persistence. Contact us today to request a custom quote and accelerate your breakthroughs.

Reference

Penter, Livius et al. "Natural Barcodes for Longitudinal Single Cell Tracking of Leukemic and Immune Cell Dynamics." Frontiers in immunology vol. 12 788891. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2021.788891.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.